Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
TCRX - TScan Therapeutics, Inc.
Market Cap 103.10M P/E - EPS this Y 13.20% Ern Qtrly Grth -
Income -104.41M Forward P/E -0.75 EPS next Y -9.30% 50D Avg Chg -13.00%
Sales 12.2M PEG - EPS past 5Y - 200D Avg Chg -11.00%
Dividend N/A Price/Book 0.67 EPS next 5Y - 52W High Chg -64.00%
Recommedations 1.70 Quick Ratio 7.72 Shares Outstanding 48.70M 52W Low Chg 50.00%
Insider Own 0.88% ROA -20.16% Shares Float 25.68M Beta 0.78
Inst Own 99.46% ROE -46.84% Shares Shorted/Prior 1.80M/1.25M Price 2.17
Gross Margin - Profit Margin - Avg. Volume 1,562,280 Target Price 12.57
Oper. Margin -6,364.55% Earnings Date - Volume 32,734 Change -0.91%
Healthcare | Biotechnology | United States
About TScan Therapeutics, Inc.

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

TScan Therapeutics, Inc. News
12/26/24 TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium
12/25/24 With 52% ownership, TScan Therapeutics, Inc. (NASDAQ:TCRX) boasts of strong institutional backing
12/23/24 TScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley Bank
12/09/24 TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA™ Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition
12/05/24 TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years
12/02/24 TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Heme Development Strategy
11/14/24 TScan Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
11/12/24 TScan Therapeutics, Inc. (TCRX) Reports Q3 Loss, Misses Revenue Estimates
11/12/24 TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
11/07/24 TScan Therapeutics (TCRX) Soars 7.6%: Is Further Upside Left in the Stock?
11/05/24 TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition
10/04/24 TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting
08/29/24 TScan Therapeutics to Participate in Upcoming Investor Conferences
08/29/24 Director of TScan Therapeutics Barbara Klencke Buys 18% More Shares
08/12/24 TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Lags Revenue Estimates
08/12/24 TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
06/24/24 TScan Therapeutics Decline Means Insider Profits Down To US$54k
06/24/24 Strength Seen in Zealand Pharma AS (ZLDPF): Can Its 11.6% Jump Turn into More Strength?
06/14/24 TScan Therapeutics Announces Updates to its Board of Directors
05/30/24 TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
BARBERICH TIMOTHY J Director Director Dec 18 Buy 4.93 29,147 143,695 67,027 12/21/23
BARBERICH TIMOTHY J Director Director Jun 02 Buy 2.6284 37,880 99,564 37,880 06/06/23
Lynx1 Capital Management LP 10% Owner 10% Owner May 31 Sell 2.51 25,400 63,754 5,224,600 06/02/23
BAKER BROS. ADVISORS LP Director Director May 10 Buy 1.89 1,359,792 2,570,007 2,528,583 05/12/22